Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Oncogenic osteomalacia 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 2gallium Ga 68 dotatate 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2lanreotide 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1X-Rays 1Radiosurgery 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1E-7386 1Disulfides 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gastro-enteropancreatic neuroendocrine tumor × gallium Ga 68 dotatate × Clear all
NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University

Phase 1 Recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Stanford University

Phase 1 Recruiting
10 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡